Onconova Therapeutics Inc Stock Nasdaq
Equities
US68232V3069
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 210K | Sales 2025 * | 300K | Capitalization | 14.4M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -28M | EV / Sales 2024 * | 68.5 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 48 x |
P/E ratio 2024 * |
-0.79
x | P/E ratio 2025 * |
-0.82
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.1% |
Latest transcript on Onconova Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 15-01-18 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 13-08-31 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 15-06-30 |
Jack Stover
BRD | Director/Board Member | 69 | 16-05-22 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 20-03-31 |
1st Jan change | Capi. | |
---|---|---|
-1.78% | 41.36B | |
+45.32% | 41.3B | |
+4.01% | 39.61B | |
-15.14% | 25.62B | |
+3.16% | 24.09B | |
-24.08% | 18.38B | |
-2.67% | 11.82B | |
+24.76% | 11.85B | |
+7.01% | 11.07B |